Format

Send to

Choose Destination
Leuk Res. 2002 Sep;26(9):881-4.

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.

Author information

1
Department of Leukemia, M.D. Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA.

Abstract

Idiopathic hypereosinophilic syndrome (HES) is a rare hematologic disorder characterized by persistent eosinophilia with organ involvement. Patients with HES have a poor prognosis, but the disease course can be heterogeneous. Treatment of HES has included corticosteroids, chemotherapeutic agents such as cyclophosphamide, vincristine, hydroxyrea, and most recently interferon-alpha (IFN-alpha) which has shown long-term beneficial effects. We herein report on a patient with HES who had disease resistant to steroids, and chemotherapy with 2-chlorodeoxyadenosine and cytarabine, but who had a significant response after only 8 days of treatment with imatinib mesylate 100mg daily. The possible mechanism of response is discussed. This observation may lead to a better understanding of the pathophysiology of HES, and may provide a new form of effective therapy for the disease.

PMID:
12127565
DOI:
10.1016/s0145-2126(02)00046-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center